{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:25:48Z","timestamp":1790799948204,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ygyno.2011.04.046","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T04:08:03Z","timestamp":1306296483000},"page":"233-237","source":"Crossref","is-referenced-by-count":45,"title":["Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers"],"prefix":"10.1016","volume":"122","author":[{"given":"Kazuya","family":"Kudoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morikazu","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.04.046_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2007","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ijc.20649","article-title":"Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953\u20132000","volume":"113","author":"Bray","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1525-1438.2003.13602.x","article-title":"Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5","volume":"13","author":"Bookman","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0025","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2006.05.006","article-title":"Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer","volume":"102","author":"Monk","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","article-title":"Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis","volume":"107","author":"Wright","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0040","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","article-title":"Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening","volume":"107","author":"Simpkins","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"18s","key":"10.1016\/j.ygyno.2011.04.046_bb0050","article-title":"Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: a gynecologic oncology group (GOG) study","volume":"28","author":"Burger","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2011.04.046_bb0055","volume":"21","author":"Perren","year":"2010","journal-title":"Ann Oncol"},{"issue":"18 Suppl","key":"10.1016\/j.ygyno.2011.04.046_bb0060","article-title":"Combination of bevacizmab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR)","volume":"24","author":"Haddad","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10 Suppl","key":"10.1016\/j.ygyno.2011.04.046_bb0065","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2011.04.046_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ncponc0637","article-title":"Ovarian cancer: a focus on management of recurrent disease","volume":"3","author":"Herzog","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0080","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0085","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0095","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000320602","article-title":"Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"79","author":"S\u00e1nchez-Mu\u00f1oz","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2009.08.032","article-title":"Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer","volume":"115","author":"Hurt","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.01.038","article-title":"What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?","volume":"105","author":"Han","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.046_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","article-title":"Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?","volume":"118","author":"Richardson","year":"2010","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T04:12:09Z","timestamp":1560226329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0090825811003477"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.04.046","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}